Update in medical oncology for older patients: Focus on breast cancer: Management of early breast cancer

Cancer Journal

Volumn 11, Issue 6, 2005, Pages 506-517

  Witherby, S M ^a,b   Muss, Hyman B ^a,b  

^a Vermont Cancer Center ^*

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Aged; Aromatase inhibitors; Breast cancer; Breast neoplasms; Endocrine therapy; Geriatrics; Selective estrogen receptor modulators

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

ARTHRALGIA; ARTHRITIS; BRAIN ISCHEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; ENDOMETRIUM CANCER; FRACTURE; HOT FLUSH; HUMAN; IRRADIATION; ISCHEMIC HEART DISEASE; LYMPH NODE DISSECTION; MEDICAL LITERATURE; META ANALYSIS; MYALGIA; ONCOLOGY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VAGINA BLEEDING; VAGINA DISCHARGE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TAMOXIFEN;

EID: 30744476509     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200511000-00010     Document Type: Review

References (84)

1. From the Centers for Disease Control and Prevention. Public health and aging: trends in aging-United States and worldwide. JAMA 2003;289:1371-1373.
2. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J.Clin 2005;55:10-30.
3. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
4. Schairer C, Mink PJ, Carroll L et al. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004;96:1311-1321.
5. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-556.
6. Eppenberger-Castori S, Moore DH Jr., Thor AD et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002;34:1318-1330.
7. Basche M, Byers T. Re: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2001;93:64-65.
8. Weiss NS. Re: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2001;93: 65-66.
9. Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer 2004;100:1807-1813.
10. Vinh-Hung V, Royce M, Verschraegen C et al. Age-patterns of mortality in early breast cancer: a graphical presentation [abstract]. Breast Cancer Res Treat 2004;88(suppl 1), Abstract 5042.
11. Bouchardy C, Rapiti E, Fioretta G et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003;21:3580-3587.
12. Hebert-Croteau N, Brisson J, Latreille J et al. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 1999;85:1104-1113.
13. Turnbull AD, Gundy E, Howland WS et al. Surgical mortality among the elderly. An analysis of 4,050 operations (1970-1974). Clin Bull 1978;8:139-142.
14. Singletary SE, Shallenberger R, Guinee VF. Breast cancer in the elderly. Ann Surg 1993;218:667-671.
15. August DA, Rea T, Sondak VK. Age-related differences in breast cancer treatment. Ann Surg Oncol 1994;1:45-52.
16. Lazovich D, Solomon CC, Thomas DB et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer 1999;86:628-637.
17. Morrow M, White J, Moughan J et al. Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 2001;19:2254-2262.
18. O'Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 2004;11:962-969.
19. Wanebo HJ, Cole B, Chung M et al. Is surgical management compromised in elderly patients with breast cancer? Ann Surg 1997;225:579-586.
20. Bradbeer JW, Kyngdon J. Primary treatment of breast cancer in elderly women with Tamoxifen. Clin Oncol 1983;9:31-34.
21. Akhtar SS, Allan SG, Rodger A et al. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol 1991;17:30-35.
22. Fentiman IS, Christiaens MR, Paridaens R et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003;39:309-316.
23. Robertson JF, Ellis IO, Elston CW et al. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992;28A:908-910.
24. Gazet JC, Ford HT, Coombes RC et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994;20:207-214.
25. Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-420.
26. Fennessy M, Bates T, MacRae K et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004;91:699-704.
27. Mandelblatt JS, Kerner JF, Hadley J et al. Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white. Cancer 2002;95:1401-1414.
28. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-553.
29. Gennari R, Rotmensz N, Perego E et al. Sentinel node biopsy in elderly breast cancer patients. Surg Oncol 2004;13:193-196.
30. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-1241.
31. Fyles AW, McCready DR, Manchul LA et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963-970.
32. Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-977.
33. Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 2004;96:115-121.
34. Truong PT, Bernstein V, Speers C et al. Omission of radiotherapy after breast conserving surgery adversely impacts survival in elderly women [abstract]. Breast Cancer Res Treat 2002;76: 36.
35. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;96-102.
36. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174.
37. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
38. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
39. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709-1717.
40. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.
41. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
42. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-942.
43. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 1998;351:1451-1467.
44. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-1081.
45. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361: 296-300.
46. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
47. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
48. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
49. Jakesz R, Kaufmann M, Gnant M et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial [abstract]. Breast Cancer Res Treat 2004;88:S7.
50. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349: 1793-1802.
51. Goss PE, Ingle JN, Martino S et al. Updated analysis of the NCIC CTG MA. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract]. Proc Am Soc Clin Oncol 2004;23:87. Abstract 847.
52. Punglia RS, Kuntz KM, Winer E et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early stage breast cancer: a decision analysis [abstract]. Breast Cancer Res Treat 2004;88:S58.
53. Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of post-menopausal hormone receptor-positive breast cancer [Aabstract]. Proc Am Soc Clin Oncol 2005;23:43s. Abstract 658.
54. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
55. Desch CE, Hillner BE, Smith TJ et al. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993;11:777-782.
56. Fisher B, Jeong JH, Anderson S et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96: 1823-1831.
57. Fisher B, Jeong JH, Bryant J et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-868.
58. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-1081.
59. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-1422.
60. Fargeot P, Bonneterre J, Roche H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004;22:4622-4630.
61. Lichtman SM, Skirvin JA. Pharmacology of antineoplastic agents in older cancer patients. Oncology (Huntingt) 2000;14: 1743-1755.
62. National Comprehensive Cancer Network. Guidelines to Supportive Care: Myeloid Growth Factors. Clinical Practice Guidelines in Oncology, v2.2005. Available at: http://www.nccn.org/professionals/physicians_gls/PDF/myeloid_ growth.pdf.
63. Lyman GH, Kuderer N, Agboola O et al. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003;10:487-499.
64. Repetto L, Biganzoli L, Koehne CH et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003;39: 2264-2272.
65. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
66. Dees EC, O'Reilly S, Goodman SN et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-529.
67. Kimmick GG, Shelton BJ, Case LD et al. Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. Breast Cancer Res Treat 2002;72:233-243.
68. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-4642.
69. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
70. DeMaio E, Gravina A, Pacilio C et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single center experience. BMC Cancer 2005;5:30.
71. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1404-1413.
72. Yardley DA, Loesch DM, Greco FA et al. Preliminary toxicity results from a phase III multi-centered trial comparing weekly docetaxel to CMP as adjuvant treatment for high risk breast cancer patients who are not candidates for anthracyclines [abstr]. Breast Cancer Res Treat 2004;88(suppl 1):S72, Abstract 1061.
73. Hurria A, Brogan K, Panageas KS et al. Pattern of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2005;92:151-156.
74. Sledge GW Jr, Romond EH, Piccart-Gebhart MJ. Advances in monoclonal antibody therapy for breast cancer. Late-breaking Scientific Symposium presented at: Annual Meeting of the American Society of Clinical Oncology; May 14-17, 2005; Orlando, FL.
75. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
76. Siminoff LA, Zhang A, Saunders Sturm CM et al. Referral of breast cancer patients to medical oncologists after initial surgical management [see comments]. Med Care 2000;38:696-704.
77. Kemeny M, Muss HB, Kornblith AB et al. Barriers to participation of older women with breast cancer in clinical trials [abstract]. Proc Am Soc Clin Oncol 2000;19:602a. Abstract 2371.
78. Kemeny MM, Peterson BL, Kornblith AB et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-2275.
79. Lara PN Jr, Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001;19:1728-1733.
80. Kornblith AB, Kemeny M, Peterson BL et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002;95:989-996.
81. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
82. Paik S, Shak S, Tang C et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. Proc Am Soc Clin Oncol 2005;23:6s. Abstract 510.
83. Duffy S, on behalf of the ATAC Trialists' Group. Gynecological adverse events including hysterectomy occur less frequently with anastrozole than with tamoxifen: Data from the ATAC ('Arimidex,' Tamoxifen, Alone or in Combination) trial [abstract]. Proc Am Soc Clin Oncol 2005;23:58s. Abstract 723.
84. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349: 1793-1802.